FindTrial
Sign In

Enteral supplementation with Bifidobacterium animalis Bb-12 modulates gut microbiome and improves intestinal barrier in very preterm infants: a randomized, controlled trial

Study on the effects of early probiotic intervention on intestinal flora, intestinal mucosal barrier and immune function in very preterm infants

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085729
Enrollment
Unknown
Registered
2024-06-17
Start date
2022-09-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal gastrointestinal disorders

Interventions

experimental group:Supplementation with Bifidobacterium animalis BB12 (brand: DiPro, manufacturer: hr.Hansen/S, Denmark, 1 billion CFU of Bifidobacterium animalis per 6 drops), 6 drops per day, mixed
control subjects:Equivalent dose of 5 per cent dextrose

Sponsors

Quanzhou Maternal and Child Health Hospital-Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Breastfeeding of preterm infants admitted to the hospital within 24 hours of birth and with a gestational age of less than 32 weeks

Exclusion criteria

Exclusion criteria: Maternal or neonatal antibiotic use, congenital gastrointestinal malformations or other severe malformations, incomplete perinatal data, and automatic discharge during the study period.

Design outcomes

Primary

MeasureTime frame
intestinal flora;Serum zonulin protein;fecal calreticulin;—

Countries

China

Contacts

Public ContactXu Jinglin

Quanzhou Maternal and Child Health Hospital-Children's Hospital, No.700 Fengze Street, Quanzhou, Fujian, China

363142715@qq.com+86 136 7597 6806

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026